{"url_path":"/sec/cycn/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1755237/0001193125-26-219478-index.html","accession_number":"0001193125-26-219478","cik":"0001755237","ticker":"CYCN","issuer_name":"Korsana Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1755237/0001193125-26-219478-index.html","primary_entity_key":"0001755237","primary_entity_name":"Cyclerion Therapeutics, Inc."},"word_count":27,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nDuring the 2026 first quarter, no director or Section 16 officer adopted or terminated any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements."}